Literature DB >> 33435159

Mechanisms of Bone Fragility: From Osteogenesis Imperfecta to Secondary Osteoporosis.

Ahmed El-Gazzar1, Wolfgang Högler1.   

Abstract

Bone material strength is determined by several factors, such as bone mass, matrix composition, mineralization, architecture and shape. From a clinical perspective, bone fragility is classified as primary (i.e., genetic and rare) or secondary (i.e., acquired and common) osteoporosis. Understanding the mechanism of rare genetic bone fragility disorders not only advances medical knowledge on rare diseases, it may open doors for drug development for more common disorders (i.e., postmenopausal osteoporosis). In this review, we highlight the main disease mechanisms underlying the development of human bone fragility associated with low bone mass known to date. The pathways we focus on are type I collagen processing, WNT-signaling, TGF-ß signaling, the RANKL-RANK system and the osteocyte mechanosensing pathway. We demonstrate how the discovery of most of these pathways has led to targeted, pathway-specific treatments.

Entities:  

Keywords:  Juvenile Paget disease; bone fragility; extracellular matrix; osteogenesis imperfecta; osteomalacia; osteopetrosis; post-translational modifications; type I collagen

Mesh:

Substances:

Year:  2021        PMID: 33435159      PMCID: PMC7826666          DOI: 10.3390/ijms22020625

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  130 in total

Review 1.  Microgravity and bone cell mechanosensitivity.

Authors:  E H Burger; J Klein-Nulend
Journal:  Bone       Date:  1998-05       Impact factor: 4.398

2.  Quantifying the osteocyte network in the human skeleton.

Authors:  Pascal R Buenzli; Natalie A Sims
Journal:  Bone       Date:  2015-02-20       Impact factor: 4.398

3.  Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis.

Authors:  A E Hughes; S H Ralston; J Marken; C Bell; H MacPherson; R G Wallace; W van Hul; M P Whyte; K Nakatsuka; L Hovy; D M Anderson
Journal:  Nat Genet       Date:  2000-01       Impact factor: 38.330

4.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.

Authors:  H Yasuda; N Shima; N Nakagawa; S I Mochizuki; K Yano; N Fujise; Y Sato; M Goto; K Yamaguchi; M Kuriyama; T Kanno; A Murakami; E Tsuda; T Morinaga; K Higashio
Journal:  Endocrinology       Date:  1998-03       Impact factor: 4.736

5.  Self-assembled RANK induces osteoclastogenesis ligand-independently.

Authors:  Kiyoshi Kanazawa; Akira Kudo
Journal:  J Bone Miner Res       Date:  2005-07-11       Impact factor: 6.741

6.  Clinical and molecular analysis in families with autosomal recessive osteogenesis imperfecta identifies mutations in five genes and suggests genotype-phenotype correlations.

Authors:  José A Caparrós-Martin; María Valencia; Veronica Pulido; Victor Martínez-Glez; Inmaculada Rueda-Arenas; Khalda Amr; Chantal Farra; Pablo Lapunzina; Victor L Ruiz-Perez; Samia Temtamy; Mona Aglan
Journal:  Am J Med Genet A       Date:  2013-04-23       Impact factor: 2.802

Review 7.  Disuse and deconditioning in chronic low back pain: concepts and hypotheses on contributing mechanisms.

Authors:  Jeanine A Verbunt; Henk A Seelen; Johan W Vlaeyen; Geert J van de Heijden; Peter H Heuts; Kees Pons; J Andre Knottnerus
Journal:  Eur J Pain       Date:  2003       Impact factor: 3.931

8.  Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity.

Authors:  Johanna Korvala; Harald Jüppner; Outi Mäkitie; Etienne Sochett; Dirk Schnabel; Stefano Mora; Cynthia F Bartels; Matthew L Warman; Donald Deraska; William G Cole; Heini Hartikka; Leena Ala-Kokko; Minna Männikkö
Journal:  BMC Med Genet       Date:  2012-04-10       Impact factor: 2.103

9.  A mutation in the 5'-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus.

Authors:  Oliver Semler; Lutz Garbes; Katharina Keupp; Daniel Swan; Katharina Zimmermann; Jutta Becker; Sandra Iden; Brunhilde Wirth; Peer Eysel; Friederike Koerber; Eckhard Schoenau; Stefan K Bohlander; Bernd Wollnik; Christian Netzer
Journal:  Am J Hum Genet       Date:  2012-08-02       Impact factor: 11.043

10.  MBTPS2 mutations cause defective regulated intramembrane proteolysis in X-linked osteogenesis imperfecta.

Authors:  Uschi Lindert; Wayne A Cabral; Surasawadee Ausavarat; Siraprapa Tongkobpetch; Katja Ludin; Aileen M Barnes; Patra Yeetong; Maryann Weis; Birgit Krabichler; Chalurmpon Srichomthong; Elena N Makareeva; Andreas R Janecke; Sergey Leikin; Benno Röthlisberger; Marianne Rohrbach; Ingo Kennerknecht; David R Eyre; Kanya Suphapeetiporn; Cecilia Giunta; Joan C Marini; Vorasuk Shotelersuk
Journal:  Nat Commun       Date:  2016-07-06       Impact factor: 14.919

View more
  10 in total

1.  A novel COL1A1 deletion/insertion pathogenic variant in a patient with osteogenesis imperfecta.

Authors:  Chieko Yamada; Takuo Kubota; Takeshi Ishimi; Shinji Takeyari; Kenichi Yamamoto; Hirofumi Nakayama; Yasuhisa Ohata; Makoto Fujiwara; Taichi Kitaoka; Keiichi Ozono
Journal:  Clin Pediatr Endocrinol       Date:  2022-06-17

2.  Increased Osteocyte Lacunae Density in the Hypermineralized Bone Matrix of Children with Osteogenesis Imperfecta Type I.

Authors:  Matthias Mähr; Stéphane Blouin; Martina Behanova; Barbara M Misof; Francis H Glorieux; Jochen Zwerina; Frank Rauch; Markus A Hartmann; Nadja Fratzl-Zelman
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

3.  Anesthetic management of ventricular-peritoneal shunt implantation in osteogenesis imperfecta type IIB: A case report.

Authors:  Mayumi To; Kota Kamizato; Hayato Shinzato; Manabu Kakinohana
Journal:  Medicine (Baltimore)       Date:  2022-01-07       Impact factor: 1.889

Review 4.  A Roadmap to Gene Discoveries and Novel Therapies in Monogenic Low and High Bone Mass Disorders.

Authors:  Melissa M Formosa; Dylan J M Bergen; Celia L Gregson; Antonio Maurizi; Anders Kämpe; Natalia Garcia-Giralt; Wei Zhou; Daniel Grinberg; Diana Ovejero Crespo; M Carola Zillikens; Graham R Williams; J H Duncan Bassett; Maria Luisa Brandi; Luca Sangiorgi; Susanna Balcells; Wolfgang Högler; Wim Van Hul; Outi Mäkitie
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-13       Impact factor: 5.555

5.  A Network Pharmacology-Based Study on Vital Pharmacological Pathways and Targets of Eucommiae Cortex Acting on Osteoporosis.

Authors:  Libo Zhou; Tao Wu
Journal:  Biomed Res Int       Date:  2022-03-31       Impact factor: 3.411

Review 6.  Osteoporosis in children and adolescents: when to suspect and how to diagnose it.

Authors:  Silvia Ciancia; Rick R van Rijn; Wolfgang Högler; Natasha M Appelman-Dijkstra; Annemieke M Boot; Theo C J Sas; Judith S Renes
Journal:  Eur J Pediatr       Date:  2022-04-06       Impact factor: 3.860

7.  SMAD3 mutation in LDS3 causes bone fragility by impairing the TGF-β pathway and enhancing osteoclastogenesis.

Authors:  Ahmed El-Gazzar; Heeseog Kang; Nadja Fratzl-Zelman; Emma Webb; Aileen M Barnes; Milena Jovanovic; Sarju G Mehta; Vipan Datta; Vrinda Saraff; Ryan K Dale; Frank Rauch; Joan C Marini; Wolfgang Högler
Journal:  Bone Rep       Date:  2022-07-16

8.  X-Linked Osteogenesis Imperfecta Possibly Caused by a Novel Variant in PLS3.

Authors:  Petar Brlek; Darko Antičević; Vilim Molnar; Vid Matišić; Kristina Robinson; Swaroop Aradhya; Dalibor Krpan; Dragan Primorac
Journal:  Genes (Basel)       Date:  2021-11-23       Impact factor: 4.096

9.  Effects of Long-Term Pamidronate Treatment on Bone Density and Fracture Rate in 65 Osteogenesis Imperfecta Patients.

Authors:  Hakan Yazan; Nilay Güneş; Evren Akpınar; Osman Nuri Özyalvaç; Dilek Uludağ Akkaya; Beyhan Tuysuz
Journal:  Turk Arch Pediatr       Date:  2021-09

10.  A systematic review and meta-analysis on the efficacy of stem cell therapy on bone brittleness in mouse models of osteogenesis imperfecta.

Authors:  Lauren Battle; Shoshana Yakar; Alessandra Carriero
Journal:  Bone Rep       Date:  2021-07-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.